465
Views
26
CrossRef citations to date
0
Altmetric
Original Articles: Research

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts

, , , , , , & show all
Pages 1536-1542 | Received 05 Mar 2010, Accepted 28 Apr 2010, Published online: 08 Jun 2010

References

  • Dohner H, Estey EH, Amadori S, et al Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
  • McCauley DL. Treatment of adult acute leukemia. Clin Pharm 1992;11:767–796.
  • Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163.
  • Lancet J, Feldman E, Cortes J, et al Phase IIb randomized study of CPX-351 vs. conventional cytarabine + daunorubicin in newly diagnosed AML patients aged 60–75: safety report. Blood 2009;114(Suppl. 1): 427 (Abstract 1033).
  • Harasym TO, Liboiron BD, Mayer LD. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol 2010;596:291–323.
  • Mayer LD, Harasym TO, Tardi PG, et al Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854–1863.
  • Tardi P, Johnstone S, Harasym N, et al In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129–139.
  • Feldman EJ, Lancet J, Kolitz JE, et al Phase I study of a liposomal carrier (CPX-351) containing a synergistic, fixed molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) in advanced leukemias. Blood 2008;112(Suppl. 1): 1025 (Abstract 2984).
  • Lim W-S, Tardi PG, Dos Santos N, et al Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010 Feb 5. [Epub ahead of print].
  • Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001;21:1004–1010.
  • Tait JF, Smith C. Phosphatidylserine receptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. J Biol Chem 1999;274:3048–3054.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.